Research programme: vaccines - CyTuVax
Alternative Names: PanCaVaxLatest Information Update: 25 Aug 2023
Price :
$50 *
At a glance
- Originator CyTuVax
- Class Vaccines
- Mechanism of Action Immunogenetic stimulants; Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Preclinical Malignant melanoma; Pancreatic cancer
- Discontinued Cytomegalovirus infections
Most Recent Events
- 25 Aug 2023 Preclinical development in Pancreatic-cancer and Malignant melanoma still ongoing
- 25 Aug 2023 Discontinued - Preclinical for Cytomegalovirus infections (Prevention) in Netherlands (unspecified route) before August 2023
- 28 Dec 2019 No recent reports of development identified for preclinical development in Cytomegalovirus infections(Prevention) in Netherlands